143 related articles for article (PubMed ID: 35967575)
21. Germline CBL mutation associated with a noonan-like syndrome with primary lymphedema and teratoma associated with acquired uniparental isodisomy of chromosome 11q23.
Hanson HL; Wilson MJ; Short JP; Chioza BA; Crosby AH; Nash RM; Marks KJ; Mansour S
Am J Med Genet A; 2014 Apr; 164A(4):1003-9. PubMed ID: 24458550
[TBL] [Abstract][Full Text] [Related]
22. VAV1-Cre mediated hematopoietic deletion of CBL and CBL-B leads to JMML-like aggressive early-neonatal myeloproliferative disease.
An W; Mohapatra BC; Zutshi N; Bielecki TA; Goez BT; Luan H; Iseka F; Mushtaq I; Storck MD; Band V; Band H
Oncotarget; 2016 Sep; 7(37):59006-59016. PubMed ID: 27449297
[TBL] [Abstract][Full Text] [Related]
23. Somatic mosaicism for a NRAS mutation associates with disparate clinical features in RAS-associated leukoproliferative disease: a report of two cases.
Shiota M; Yang X; Kubokawa M; Morishima T; Tanaka K; Mikami M; Yoshida K; Kikuchi M; Izawa K; Nishikomori R; Okuno Y; Wang X; Sakaguchi H; Muramatsu H; Kojima S; Miyano S; Ogawa S; Takagi M; Hata D; Kanegane H
J Clin Immunol; 2015 Jul; 35(5):454-8. PubMed ID: 25896945
[TBL] [Abstract][Full Text] [Related]
24. Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia.
Hecht A; Meyer JA; Behnert A; Wong E; Chehab F; Olshen A; Hechmer A; Aftandilian C; Bhat R; Choi SW; Chonat S; Farrar JE; Fluchel M; Frangoul H; Han JH; Kolb EA; Kuo DJ; MacMillan ML; Maese L; Maloney KW; Narendran A; Oshrine B; Schultz KR; Sulis ML; Van Mater D; Tasian SK; Hofmann WK; Loh ML; Stieglitz E
Haematologica; 2022 Jan; 107(1):178-186. PubMed ID: 33375775
[TBL] [Abstract][Full Text] [Related]
25. Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome.
Lasho T; Patnaik MM
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101171. PubMed ID: 32460983
[TBL] [Abstract][Full Text] [Related]
26. Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.
Muramatsu H; Makishima H; Jankowska AM; Cazzolli H; O'Keefe C; Yoshida N; Xu Y; Nishio N; Hama A; Yagasaki H; Takahashi Y; Kato K; Manabe A; Kojima S; Maciejewski JP
Blood; 2010 Mar; 115(10):1969-75. PubMed ID: 20008299
[TBL] [Abstract][Full Text] [Related]
27. RASopathy-associated CBL germline mutations cause aberrant ubiquitylation and trafficking of EGFR.
Brand K; Kentsch H; Glashoff C; Rosenberger G
Hum Mutat; 2014 Nov; 35(11):1372-81. PubMed ID: 25178484
[TBL] [Abstract][Full Text] [Related]
28. Chronic myeloproliferative neoplasm in adulthood in CBL syndrome harboring a splice-site
Mason G; Aghajani R; Dance B; Othman J; Goodwin L; Stevenson W; Mackinlay N
EJHaem; 2024 Apr; 5(2):397-402. PubMed ID: 38633130
[TBL] [Abstract][Full Text] [Related]
29. Molecular Diversity and Associated Phenotypic Spectrum of Germline CBL Mutations.
Martinelli S; Stellacci E; Pannone L; D'Agostino D; Consoli F; Lissewski C; Silvano M; Cencelli G; Lepri F; Maitz S; Pauli S; Rauch A; Zampino G; Selicorni A; Melançon S; Digilio MC; Gelb BD; De Luca A; Dallapiccola B; Zenker M; Tartaglia M
Hum Mutat; 2015 Aug; 36(8):787-96. PubMed ID: 25952305
[TBL] [Abstract][Full Text] [Related]
30. Gain-of-function mutations in CARD11 promote enhanced aggregation and idiosyncratic signalosome assembly.
Stinson JR; Dorjbal B; McDaniel DP; David L; Wu H; Snow AL
Cell Immunol; 2020 Jul; 353():104129. PubMed ID: 32473470
[TBL] [Abstract][Full Text] [Related]
31. Embryonal rhabdomyosarcoma in a patient with a germline CBL pathogenic variant.
Ji J; Navid F; Hiemenz MC; Kaneko M; Zhou S; Saitta SC; Biegel JA
Cancer Genet; 2019 Feb; 231-232():62-66. PubMed ID: 30803559
[TBL] [Abstract][Full Text] [Related]
32. Mutation in NRAS in familial Noonan syndrome--case report and review of the literature.
Ekvall S; Wilbe M; Dahlgren J; Legius E; van Haeringen A; Westphal O; Annerén G; Bondeson ML
BMC Med Genet; 2015 Oct; 16():95. PubMed ID: 26467218
[TBL] [Abstract][Full Text] [Related]
33. Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation.
Takagi M; Shinoda K; Piao J; Mitsuiki N; Takagi M; Matsuda K; Muramatsu H; Doisaki S; Nagasawa M; Morio T; Kasahara Y; Koike K; Kojima S; Takao A; Mizutani S
Blood; 2011 Mar; 117(10):2887-90. PubMed ID: 21063026
[TBL] [Abstract][Full Text] [Related]
34. Congenital B cell lymphocytosis explained by novel germline CARD11 mutations.
Snow AL; Xiao W; Stinson JR; Lu W; Chaigne-Delalande B; Zheng L; Pittaluga S; Matthews HF; Schmitz R; Jhavar S; Kuchen S; Kardava L; Wang W; Lamborn IT; Jing H; Raffeld M; Moir S; Fleisher TA; Staudt LM; Su HC; Lenardo MJ
J Exp Med; 2012 Nov; 209(12):2247-61. PubMed ID: 23129749
[TBL] [Abstract][Full Text] [Related]
35. Clinical Spectrum of Ras-Associated Autoimmune Leukoproliferative Disorder (RALD).
Neven Q; Boulanger C; Bruwier A; de Ville de Goyet M; Meyts I; Moens L; Van Damme A; Brichard B
J Clin Immunol; 2021 Jan; 41(1):51-58. PubMed ID: 33011939
[TBL] [Abstract][Full Text] [Related]
36. T and B cell clonal expansion in Ras-associated lymphoproliferative disease (RALD) as revealed by next-generation sequencing.
Levy-Mendelovich S; Lev A; Rechavi E; Barel O; Golan H; Bielorai B; Neumann Y; Simon AJ; Somech R
Clin Exp Immunol; 2017 Sep; 189(3):310-317. PubMed ID: 28500641
[TBL] [Abstract][Full Text] [Related]
37. A child with juvenile myelomonocytic leukemia possessing a concurrent germline CBL mutation and a NF1 variant of uncertain significance: A rare case with a common problem in the era of high-throughput sequencing.
Wang WH; Lu MY; Tsai CH; Wang SC; Chou SW; Jou ST
J Formos Med Assoc; 2021 Apr; 120(4):1148-1152. PubMed ID: 32933826
[TBL] [Abstract][Full Text] [Related]
38. RAS diseases in children.
Niemeyer CM
Haematologica; 2014 Nov; 99(11):1653-62. PubMed ID: 25420281
[TBL] [Abstract][Full Text] [Related]
39. Unexpected Findings in a Child with Atypical Hemolytic Uremic Syndrome: An Example of How Genomics Is Changing the Clinical Diagnostic Paradigm.
Seaby EG; Gilbert RD; Andreoletti G; Pengelly RJ; Mercer C; Hunt D; Ennis S
Front Pediatr; 2017; 5():113. PubMed ID: 28589114
[No Abstract] [Full Text] [Related]
40. After 95 years, it's time to eRASe JMML.
Meynier S; Rieux-Laucat F
Blood Rev; 2020 Sep; 43():100652. PubMed ID: 31980238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
